United States Anti-Rheumatic Drug Market Size, Share, Opportunities And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals) And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2020 To 2025

Published: Jun 2020 | Report Code:  KSI061613640 | Pages:  75

United States Antirheumatic Drugs market was valued at US$5,913.744 million in 2019. As per the data from the World Bank Group, the population of ages 65 and above has increased from 40,156,009 in 2010 to 51,717,496 by 2018.With the booming geriatric population in the U.S, the demand for antirheumatic drugs in the country is poised to grow during the forecast period. Moreover, the rising number of adults with arthritis is also driving the market growth of antirheumatic drug market in the country. According to the U.S Department of Health and Human Services, almost half of the U.S adults who suffer from arthritis have persistent pain. Furthermore, it is projected that the number of adults with doctor-diagnosed arthritis will reach to around 78 million by 2040.

The presence of major market players in the country also contributes to the market growth of antirheumatic drugs in the U.S. The U.S. FDA (Food and Drug Administration) has approved many antirheumatic drugs in the recent past years, particularly in 2017, which is also boosting the country’s market growth. For example, abaloparatide as approved in April 2017 for post-menopausal women with osteoporosis and a high risk of fracture. Sarilumab was approved in May 2017to be used by patients with moderate to severe rheumatoid arthritis who have not responded well to one or more disease-modifying antirheumatic drugs (DMARDs). In August 2019, FDA approved AbbVie’s RINVOQ®, 15 mg, once-daily oral JAK (Janus Kinase) inhibitor for the treatment of moderate to severe rheumatoid arthritis in adults with zero tolerance or inadequate response to methotrexate (MTX-IR).

The United States Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the United States Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).


  • By Type of Disease
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Gout
    • Lupus
    • Others
  • By Type of Molecule
    • Pharmaceuticals
    • Biopharmaceuticals
  • By Sales Channel
    • Prescription
    • Over-The-Counter (OTC)

Explore custom options available with this study:

  • Request customization

  • Buy sections of the study

  • Buy country specific report

  • Request excel, Historical data

  • Subscription inquiry

  • Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


We are in compliance with the global privacy laws.